Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but risin

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weigh

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 milli

Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises

Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweigh

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downg

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks

Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, u

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.99) per share which missed the an

Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY

Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) CEO Herriot Tabuteau sold 4,660 shares of

Assenagon Asset Management S.A. lowered its holdings in Axsome Therapeutics, Inc. (NASDAQ: AXSM) by

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into so

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform an

BLND, AXSM and BCML have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2026.

ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.

LEN, AXSM and SAM have been added to the Zacks Rank #5 (Strong Sell) List on July 27, 2026.

Caxton Associates LLP bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the unde

President Donald Trump has announced that all generic drugs imported into the United States would co

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

BMO Capital analyst Malcolm Hoffman initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with

AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcol

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions shou

Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revoluti

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in chi

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform

FOCUS-2 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3,

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding it

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin

Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturi